Proactive - Interviews for investors

Faron Pharmaceuticals CMO discusses positive read-out from Phase II trial of lead asset

Faron Pharmaceuticals Limited (AIM:FARN) chief medical officer Dr Petri Bono speaks with Proactive's Stephen Gunnion about the promising interim results from the phase II BEXMAB trial. This trial targets relapsed and refractory myelodysplastic syndrome (MDS) with their anti-Clever-1 antibody, bexmarilimab. Bono highlighted that BEXMAB treatment combined with azacitidine showed a median survival of 13.5 months, significantly surpassing the historical survival rate of 5 to 6 months. He noted an exceptional 80% overall response rate in patients who had no other treatment options. These results represent significant progress for this challenging patient population. Additionally, he shared that detailed clinical, translational, and safety findings would be presented at the American Society of Hematology annual meeting in December 2024. He confirmed that the full phase II results are expected by the end of Q1 2025, with enrollment ongoing in the US, Finland, and soon the UK. Visit Proactive’s YouTube channel for more interviews and updates. Don’t forget to like, subscribe, and hit the notification bell to stay informed. #FaronPharmaceuticals #BEXMAB #MDSResearch #ClinicalTrials #Hematology #CancerResearch #Bexmarilimab #MedicalBreakthroughs #PharmaNews #ProactiveUpdates #ProactiveInvestors #invest #investing #investment #investor #stockmarket #stocks #stock #stockmarketnews

Duration:: 4m
Broadcast on:: 29 Nov 2024
Audio Format:: other

Hello, you're watching Pro Action. I'm joined by Farron from a musical chief medical officer, Dr. Petri Bonner. Petri, very good to speak with you today. You've announced positive phase two interim results from your BEXMAP trial. Can you remind us about the BEXMAP trial and what it's targeting? Yes. BEXMAP is a phase two trial targeting patients with relapsed and refractory myelodysplastic syndrome with a novel agent called Bexmarilumab that is our drug in the development to treat this disease. Bexmarilumab is an anti-clever1 antibody, so targeting clever1 receptor that is expressed not just in the tumor, microenvironment, but also by the cancer cells, such so the blast cells. So the target, clever1, is also expressed by the cancer cells and we have a dual mechanism of action when we treat these melodysplastic syndrome patients. Take us through the key highlights on the interim phase two readouts, please. More than happy to tell about this because we published yesterday these top line results as a press release and really the interim phase two data read out. So it confirmed the earlier positive phase one and two findings of Bexmarilumab treatment with these patients. These patients are difficult to treat patients and having high unmet medical need. Their median overall survival is about five to six months and we were able to show in this updated analysis that their survival is when treated with BEX and ASES I said in its 13.5 months, which is significantly longer than the historical rates. Then also we were able to show that the overall response rate is extremely high with the treatment. These patients have failed earlier treatments and we were able to show 80% overall response rate to the treatment and these don't have other treatment options and it's very significant that when we have a longer follow-up and we have a large amount of patients, the earlier very positive looking results so they seem to hold nicely. So actually they became slightly better than the last data readout that was done in May 24. What's the significance of the higher overall response rate to Bexmarilumab? It shows that BEX is really having activity within relapse and refractory MDS patients. The activity is so high that it shows that actually the way Bexmarilum is tackling these blood cancer type is certainly clinically active. It's clinically meaningful, deep response is what we've seen in these patients. We have so far published only the top one result of the response rate and survival, all the deep results, what comes to the clinical, other outcomes as well as translational results, as well as safety and tolerability of the treatment that was excellent so they will be presented on December 9 at the American Society of Hematology annual meeting in San Diego US. Patrick, what's the next milestones for the trial? The next milestone is that we of course want to go to the end of the phase two. The phase two is still running and ongoing. We are still enrolling patients. We have four sites open in US and still four sites also open in Finland but we are very soon to launch two new two sites in UK and the enrollment will continue as planned and we expect to be able to relieve the results of the full pace and set at the end of Q1 in 2025. Patrick, I hope your keepers updated on any progress. Thank you very much for speaking with us today. Thank you. Nice to speak to you. That's Karen from the City Schools Chief Medical Officer, Dr. Patrick Bonner.